iSpecimen Expands Support of COVID-19 Research with Sequenced Specimens to Detect Variants

 Recent expansion of supplier capabilities will support commercial and government customers in their fight against COVID-19

 iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants. The reference lab, a recent addition to the iSpecimen supplier network, has the capacity to sequence hundreds of COVID-19 positive swabs per week, providing data that is crucial in the fight against the virus. This lab is sequencing the most recent swabs to identify new variants of COVID-19 as the virus continues to progress globally.

https://finance.yahoo.com/news/ispecimen-expands-support-covid-19-130000680.html